{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:39:37Z","timestamp":1794703177525,"version":"4.9.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.drugalcdep.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T09:55:18Z","timestamp":1558346118000},"page":"168-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study"],"prefix":"10.1016","volume":"200","author":[{"given":"Raj K.S.","family":"Badhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Gittins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Al Zabit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jama.1995.03530020061033","article-title":"Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study","volume":"274","author":"Antonucci","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.144.8.1667","article-title":"Rifampin drug interactions","volume":"144","author":"Baciewicz","year":"1984","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/archfami.4.6.541","article-title":"Tuberculosis in the homeless","volume":"4","author":"Barclay","year":"1995","journal-title":"Arch. Fam. Med."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004714-200204000-00017","article-title":"Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers","volume":"22","author":"Begre","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8023","key":"10.1016\/j.drugalcdep.2019.03.013_bib0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(77)92756-8","article-title":"Rifampicin and methadone withdrawal","volume":"1","author":"Bending","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1081\/DMR-200033432","article-title":"Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer\u2019s pioneering ideas to modern concepts","volume":"36","author":"Bolt","year":"2004","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.116793","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate","volume":"70","author":"Boulton","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.drugalcdep.2019.03.013_bib0040","first-page":"77S","article-title":"Enzyme induction and beta-adrenergic receptor blocking drugs","volume":"17","author":"Branch","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0045","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1128\/AAC.01229-13","article-title":"Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance","volume":"57","author":"Bruce","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0050","series-title":"An Evidence Review of the Outcomes That Can Be Expected of Drug Misuse Treatment in England","author":"Burkinshaw","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1213\/01.ANE.0000099723.75548.DF","article-title":"Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects","volume":"98","author":"Callahan","year":"2004","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1213\/ANE.0b013e3182918252","article-title":"Mechanism of autoinduction of methadone N-demethylation in human hepatocytes","volume":"117","author":"Campbell","year":"2013","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0065","first-page":"236","article-title":"Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET)","volume":"38","author":"Centers for Disease Control","year":"1989","journal-title":"MMWR Morbid. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0075","first-page":"985","article-title":"Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation","volume":"25","author":"Code","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsat.2014.06.001","article-title":"Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels","volume":"47","author":"D\u2019Aunno","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2125.2004.02116.x","article-title":"Bioavailabilities of rectal and oral methadone in healthy subjects","volume":"58","author":"Dale","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2165\/00003088-200746100-00002","article-title":"Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics","volume":"46","author":"Davis","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0095","doi-asserted-by":"crossref","first-page":"e4199","DOI":"10.1136\/bmj.e4199","article-title":"Rifampicin reduces methadone concentrations","volume":"344","author":"Dedicoat","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0100","article-title":"Illicit drug dependence","volume":"vol. 4","author":"Degenhardt","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1086\/594126","article-title":"Tuberculosis and illicit drug use: review and update","volume":"48","author":"Deiss","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1183\/09031936.05.00136004","article-title":"Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners","volume":"26","author":"Drobniewski","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","article-title":"Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment","volume":"61","author":"Eap","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/dmd.32.3.348","article-title":"Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers","volume":"32","author":"Faucette","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0125","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone--metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4","volume":"47","author":"Foster","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0135","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/dmd.115.064352","article-title":"Differences in methadone metabolism by CYP2B6 variants","volume":"43","author":"Gadel","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0014-2999(99)00066-7","article-title":"Induction of antibodies to methadone during methadone maintenance treatment of heroin addicts and its possible clinical implications","volume":"369","author":"Gamaleya","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0145","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00478-15","article-title":"Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone","volume":"59","author":"Garimella","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15287390490273550","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children\u2019s risks from environmental agents","volume":"67","author":"Ginsberg","year":"2004","journal-title":"J. Toxicol. Environ. Health A"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ccm.2009.08.017","article-title":"Global burden and epidemiology of tuberculosis","volume":"30","author":"Glaziou","year":"2009","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0160","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.271","article-title":"Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects","volume":"4","author":"Hagelberg","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugalcdep.2005.06.005","article-title":"Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis","volume":"81","author":"Hallinan","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0170","series-title":"Estimates of the Prevalence of Opiate Use and\/or Crack Cocaine Use, 2014\/15: Sweep 11 Report","author":"Hay","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0175","first-page":"23","article-title":"Methadone and buprenorphine added to the WHO list of essential medicines","volume":"10","author":"Herget","year":"2005","journal-title":"HIV. Policy Law Rev."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1749-6632.1975.tb19179.x","article-title":"Tuberculosis and alcoholism","volume":"252","author":"Hudolin","year":"1975","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1369-1600.2009.00158.x","article-title":"Effect of saquinavir\/ritonavir (1000\/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy","volume":"14","author":"Jamois","year":"2009","journal-title":"Addict. Biol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2125.2005.02429.x","article-title":"Modelling approaches to dose estimation in children","volume":"59","author":"Johnson","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/adc.2006.114835","article-title":"The problems in scaling adult drug doses to children","volume":"93","author":"Johnson","year":"2008","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ewjm.172.1.11","article-title":"Toxicology and pathology of deaths related to methadone: retrospective review","volume":"172","author":"Karch","year":"2000","journal-title":"West. J. Med."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0205","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1124\/dmd.118.081927","article-title":"Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance","volume":"46","author":"Kenny","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0215","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of cytochrome P4502B6 in methadone metabolism and clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0220","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0225","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0230","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","article-title":"Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir\/indinavir","volume":"110","author":"Kharasch","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0235","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.12.009","article-title":"Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity","volume":"101","author":"Kharasch","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0240","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/ALN.0b013e3182423478","article-title":"Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A)","volume":"116","author":"Kharasch","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0245","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0250","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0255","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJM197605132942008","article-title":"Rifampin-induced methadone withdrawal","volume":"294","author":"Kreek","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0260","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10550881003684798","article-title":"Pharmacotherapy in the treatment of addiction: methadone","volume":"29","author":"Kreek","year":"2010","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0265","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00315399","article-title":"Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin","volume":"45","author":"Lee","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0270","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7326\/0003-4819-126-2-199701150-00005","article-title":"Incidence of tuberculosis in the United States among HIV-infected persons","volume":"126","author":"Markowitz","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0280","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bcp.12576","article-title":"Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity","volume":"79","author":"Mouly","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0285","series-title":"Methadone and Buprenorphine for the Management of Opioid Dependence","author":"National Institute for Clinical Excellence","year":"2007"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0290","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1530-0277.1995.tb01467.x","article-title":"Alcohol, tumor necrosis factor, and tuberculosis","volume":"19","author":"Nelson","year":"1995","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0295","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin : clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0300","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/bdd.2087","article-title":"The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy","volume":"38","author":"Olafuyi","year":"2017","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2017.05.043","article-title":"Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: a case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin","volume":"106","author":"Olafuyi","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0310","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00003088-200140110-00004","article-title":"Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions","volume":"40","author":"Pea","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0315","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.forsciint.2013.01.028","article-title":"A review of methadone deaths between 2001 and 2005 in Victoria","volume":"226","author":"Pilgrim","year":"2013","journal-title":"Australia. Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0320","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1124\/dmd.118.081364","article-title":"Physiologically based pharmacokinetic model of itraconazole and two of its metabolites to improve the predictions and the mechanistic understanding of CYP3A4 drug-Drug interactions","volume":"46","author":"Prieto Garcia","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0325","series-title":"Drug Misuse and Dependence: UK Guidelines on Clinical Management","author":"Public Health England","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0330","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/bmj.313.7062.925","article-title":"Methadone maintenance and tuberculosis treatment","volume":"313","author":"Raistrick","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0335","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0340","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2125.1999.00974.x","article-title":"Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes","volume":"48","author":"Rostami-Hodjegan","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0345","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0740-5472(99)00074-4","article-title":"An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence","volume":"18","author":"Rothman","year":"2000","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0350","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective-study of the risk of tuberculosis among intravenous drug-users with human immunodeficiency virus-infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0355","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/jama.1992.03490040080029","article-title":"High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy","volume":"268","author":"Selwyn","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0360","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/bdd.2063","article-title":"Prediction of liver volume - a population-based approach to meta-analysis of paediatric, adult and geriatric populations - an update","volume":"38","author":"Small","year":"2017","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0365","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0370","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10928-018-9597-6","article-title":"Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals","volume":"45","author":"Tylutki","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0375","series-title":"Conversion Factors for Controlled Substances","author":"U.S. Department of Justice","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0380","series-title":"Summary Minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology","author":"U.S. Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0385","series-title":"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0390","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-199222010-00005","article-title":"Pharmacokinetic drug interactions with rifampicin","volume":"22","author":"Venkatesan","year":"1992","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0395","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0400","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0405","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/clinchem\/37.2.205","article-title":"Methadone concentrations in plasma and their relationship to drug dosage","volume":"37","author":"Wolff","year":"1991","journal-title":"Clin. Chem."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0410","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00315479","article-title":"Steady-state pharmacokinetics of methadone in opioid addicts","volume":"44","author":"Wolff","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0415","series-title":"WHO Model List of Essential Medicine","author":"World Health Organisation","year":"2015"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0420","series-title":"Guidelines for Treatment of Tuberculosis","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0425","series-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0430","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.drugalcdep.2019.03.013_bib0435","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/ADM.0000000000000263","article-title":"Medication adherence in patients undergoing methadone maintenance treatment in Xi\u2019an","volume":"11","author":"Zhou","year":"2017","journal-title":"China. J. Addict. Med."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619301450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619301450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:59:36Z","timestamp":1759827576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871619301450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":87,"alternative-id":["S0376871619301450"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.03.013","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}